Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Dec. 2025,
Shandong Boan Biotechnology Co received€86.52 Mil more from issuing new shares than it paid to buy back shares.
It spent€2.30 Mil paying down its debt.
It paid€0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received€0.00 Mil from paying cash dividends to shareholders.
It spent€2.20 Mil on other financial activities.
In all, Shandong Boan Biotechnology Coearned€82.02 Mil on financial activities for the
six
months ended in Dec. 2025.
Shandong Boan Biotechnology Co (FRA:UJ9) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Shandong Boan Biotechnology Co's issuance of stock for the
six
months ended in Dec. 2025 was €86.52 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Shandong Boan Biotechnology Co's repurchase of stock for the
six
months ended in Dec. 2025 was €0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Shandong Boan Biotechnology Co's net issuance of debt for the
six
months ended in Dec. 2025 was €-2.30 Mil.
Shandong Boan Biotechnology Co spent€2.30 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Shandong Boan Biotechnology Co's net issuance of preferred for the
six
months ended in Dec. 2025 was €0.00 Mil.
Shandong Boan Biotechnology Co paid€0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Shandong Boan Biotechnology Co's cash flow for dividends for the
six
months ended in Dec. 2025 was €0.00 Mil.
Shandong Boan Biotechnology Co received€0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Shandong Boan Biotechnology Co's other financing for the
six
months ended in Dec. 2025 was €-2.20 Mil.
Shandong Boan Biotechnology Co spent€2.20 Mil on other financial activities.
Shandong Boan Biotechnology Co Cash Flow from Financing Related Terms
Shandong Boan Biotechnology Co Cash Flow from Financing Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Boan Biotechnology Co Cash Flow from Financing Chart
Shandong Boan Biotechnology Co Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €138.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of €138.10 Mil mean?
Shandong Boan Biotechnology Co (FRA:UJ9) has a Cash Flow from Financing of €138.10 Mil as of Dec. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Shandong Boan Biotechnology Co and its competitors.
Is Shandong Boan Biotechnology Co's Cash Flow from Financing too high?
Shandong Boan Biotechnology Co's current Cash Flow from Financing is €138.10 Mil. Overall, Shandong Boan Biotechnology Co has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Boan Biotechnology Co's Cash Flow from Financing compare to VRTX and REGN?
Shandong Boan Biotechnology Co's Cash Flow from Financing of €138.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Shandong Boan Biotechnology Co and its competitors. Shandong Boan Biotechnology Co's current Cash Flow from Financing is €138.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Boan Biotechnology Co stock overvalued right now?
Shandong Boan Biotechnology Co (FRA:UJ9) has a current Cash Flow from Financing of €138.10 Mil. The stock's GF Value™ is €1.76, compared to a current price of €0.40 — trading 77% below its estimated fair value. The current Cash Flow from Financing is €138.10 Mil. Shandong Boan Biotechnology Co's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Shandong Boan Biotechnology Co (FRA:UJ9), the current Cash Flow from Financing is €138.10 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Boan Biotechnology Co (FRA:UJ9) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Boan Biotechnology Co stock appears to be undervalued.
The current stock price of €0.40 is trading 77% below its estimated GF Value™ of €1.76.
Key valuation signals for FRA:UJ9:
Cash Flow from Financing: €138.10 Mil
GF Value™: €1.76 vs. price of €0.40 (77% below fair value)
No single metric tells the full story. See the FRA:UJ9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. It is focused on developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Fully Human Antibody Platform, bsAb/msAb/Probody Platform, and ADC Platform. It has commercialized several products, such as Boyounuo, Boyoubei (denosumab injection 60 mg), Boluojia (denosumab injection 120 mg), Boyouping (dulaglutide injection), and Boyoujing; and is actively engaged in the development of other drugs like BA1104 (nivolumab injection), BA1106, BA1302 (an anti-CD228 ADC), etc. Geographically, the company generates maximum revenue from the Chinese mainland.
42GF Score
Get the complete analysis for FRA:UJ9
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UJ9 has been successfully added to your 
